(Total Views: 687)
Posted On: 01/25/2021 2:26:24 AM
Post# of 155039
Ohm wrote:
Given good CD12 results, I believe OWS would jump in and push production. Janet Woodcock of the FDA knows Leron well. Everyone in the govt wants to turn this pandemic around quickly.
Average p/e of Nasdaq today is 25.72. Growth possibilities for CYDY are much bigger than an average NASDAQ stock. (Understatement of the year.) I'd be surprised if we didn't jump to a 40 to 1 ratio, or a $20 billion cap.
Quote:
We have no idea what the deal is with our distributor or how much we can ramp up production. If we can't ramp up production (unlikely given the worldwide demand) then we're at $2 billion revenue most likely $500 million earnings with increased trials. $500 million x 20 P/E = $10 billion market cap. With increased production, upcoming catalysts and the sheer potential it should be much higher.
Given good CD12 results, I believe OWS would jump in and push production. Janet Woodcock of the FDA knows Leron well. Everyone in the govt wants to turn this pandemic around quickly.
Average p/e of Nasdaq today is 25.72. Growth possibilities for CYDY are much bigger than an average NASDAQ stock. (Understatement of the year.) I'd be surprised if we didn't jump to a 40 to 1 ratio, or a $20 billion cap.
(3)
(0)
